Skip to content
ppharmaranks
Menu

Complement Inhibitor drugs compared

Compare all 3 Complement Inhibitor drugs side by side, used for conditions such as hemoglobinuria, paroxysmal, myasthenia gravis, atypical hemolytic uremic syndrome. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.

Full ranking · 3 drugs

  1. 1

    soliris

    Eculizumab

    70/100
  2. 2

    empaveli

    Pegcetacoplan

    New
  3. 3

    syfovre

    Pegcetacoplan

    New

Frequently asked questions

What is the Complement Inhibitor drug class?

Complement Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 3 Complement Inhibitor products, each independently rated.

Are all Complement Inhibitor drugs the same?

No. Complement Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Complement Inhibitor drugs treat?

Per NIH RxClass drug-classification data, Complement Inhibitor drugs are used for conditions including hemoglobinuria, paroxysmal, myasthenia gravis, atypical hemolytic uremic syndrome.

Sources: the Complement Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.